Crohn's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

List of Tables

Abstract

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, Canada) and provides an Excel-based forecast model for Crohn's Disease market through 2032.

GlobalData estimates Crohn's Disease (CD) drug sales across the 8MM covered in this report will increase from $9.5 billion to $15.0 billion, at a compound annual growth rate (CAGR) of 4.7%, by the end of the forecast period in 2032. The growth of the market will be driven by the approval and launches of 15 pipeline, generic, and biosimilar therapies.

Major drivers of CD market growth over the forecast period are the -

The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
Successful legal rulings in favor of pharmaceutical companies over the legality of drug price legislature in the US
Updated recommendations for the rapid incorporation of newer therapies by healthcare providers

Major barriers that will restrict the growth of the CD market during the forecast period are the -

Legislature by the US government to reduce drug prices resulting in lower sales in the largest global market
The emergence of several biosimilar and generic drugs entering the US market
Disruption of the pharmaceutical supply chain and the production of biologics due to geopolitical events

Key Highlights

GlobalData estimates that sales of drugs in the CD market was approximately $9.5 billion in 2022 in the 8MM. The global CD market is expected to grow to $15.0 billion in 2032, at a Compound Annual Growth Rate (CAGR) of 4.7%.

Major drivers of CD market growth over the forecast period are the -

The emergence within the market of novel and innovative therapies that provides significant improvement in therapeutic efficacy over current treatments
The launch of the MK-7240 companion diagnostic test
Updated recommendations for the rapid incorporation of newer therapies by healthcare providers

Scope

Overview of CD including epidemiology, disease etiology and management.
Topline CD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan, and Canada over the 10-year forecast period.
Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global CD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global CD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global CD therapeutics market from 2022-2032.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC280PIDR-8M

About GlobalData

1 Crohn's Disease: Executive Summary

1.1 Steady growth is expected for the CD market from 2022-32
1.2 Novel MOAs will provide market shifts throughout the forecast period
1.3 Lack of tools to properly treat patients with CD is a clear unmet need within the market
1.4 Pipeline Drugs
1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
- 3.1.3 CD Classification

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 8MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed incident cases of CD
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of CD
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of CD by severity, diagnosed prevalent cases of fistulizing CD by severity, and diagnosed prevalent cases of CD in remission by severity
4.5 Epidemiological forecast for Crohn's disease (2022-32)
- 4.5.1 Diagnosed incident cases of CD
- 4.5.2 Age-specific diagnosed incident cases of CD
- 4.5.3 Sex-specific diagnosed incident cases of CD
- 4.5.4 Diagnosed prevalent cases of CD
- 4.5.5 Age-specific diagnosed prevalent cases of CD
- 4.5.6 Sex-specific diagnosed prevalent cases of CD
- 4.5.7 Diagnosed prevalent cases of CD by severity
- 4.5.8 Diagnosed prevalent cases of fistulizing CD by severity
- 4.5.9 Diagnosed prevalent cases of CD in remission by severity
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Improved Drug Efficacy, Clinical Response, and Sustained Remission
7.3 Biomarkers to Predict Responsiveness to Therapy and Prognosis
7.4 Improved Medical Management of Perianal Fistulas
7.5 Clinical Data to Determine the Most Efficacious Therapy

8 R&D Strategies

8.1 Overview
- 8.1.1 Novel MOAs
- 8.1.2 Biomarkers
8.2 Clinical Trials Design
- 8.2.1 Patient inclusion criteria
- 8.2.2 Endpoints

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview
11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key Events
- 12.4.3 Drivers and barriers
12.5 Canada
- 12.5.1 Forecast
- 12.5.2 Key events
- 12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
- 13.4.1 KOLs
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Managing Analyst
- 13.6.3 Epidemiologist
- 13.6.4 Reviewers
- 13.6.5 Global Director of Therapy Analysis and Epidemiology

Product Code: GDHC280PIDR-8M

List of Tables

Table 1: CD: Key metrics in the 8MM
Table 2: Crohn's disease severities
Table 3: Risk factors and comorbidities for CD
Table 4: Treatment guidelines for CD
Table 5: Top 10 deals by value, 2011-2022
Table 6: CD market - global drivers and ba

List of Figures

Figure 1: Global sales forecast by country for CD in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in CD during the forecast period
Figure 3: Competitive assessment of the late-stage biologics benchmarked against Humira
Fig

Crohn's Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032

Description

Table of Contents

List of Tables

Abstract

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Crohn's Disease: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Tables

List of Tables

List of Figures

List of Figures